Items tagged with Drug-resistant TB
RESIST-TB June 2021 newsletter (post)
RESIST-TB released its June 2021 newsletter with the latest research publications on drug-resistant TB.
Active TB Drug Safety Monitoring and Management (aDSM) global database: Outcome of the assessment and future of data reporting (post)
6 July 2021, Geneva | A global database set up by WHO’s Global Tuberculosis Programme in collaboration with the Special Programme for Research and Training in Tropical Diseases (TDR) has been collating data on Active TB Drug Safety Monitoring and Management (aDSM) since 2016, to monitor the safety of patients who receive MDR-TB treatment with new medicines (e.g. bedaquiline, delamanid), repurposed medicines (e.g. linezolid, clofazimine) or new regimens, which don't have a well-established safety profile. The aDSM framework has been promoted by WHO and stakeholders since 2015 for monitoring safety for patients who receive MDR-TB treatment with medicines of interest and successfully implemented in many countries for ensuring safety of patients while rolling of the newly recommended MDR-TB treatment regimens.
Webinar: Challenging patent barriers in accessing new TB treatments - recording now available online (post)
On 30 June 2021, the Third World Network and People's Health Movement conducted a webinar to discuss challenges in accessing affordable new TB treatments, new treatments in the pipeline, the trends in patenting and implications for access.
ZeNix trial results show effectiveness of regimen against highly drug-resistant TB (post)
The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.
LSHTM launches new centre of innovation to tackle antimicrobial resistance and TB (post)
The London School of Hygiene & Tropical Medicine’s (LSHTM) research into tackling antimicrobial resistance and tuberculosis has been boosted through a new partnership with Johnson & Johnson.
CHMP grants positive opinion for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba (post)
CHMP grants positive opinion in the European Union for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba® (delamanid) for the paediatric population weighing at least 10 kg with pulmonary multidrug-resistant TB
RESIST-TB July 2021 newsletter (post)
RESIST-TB released its July 2021 newsletter with the latest research publications on drug-resistant TB.
TB Alliance: Community engagement virtual forum (post)
On 12 August 2021, TB Alliance will host a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.
Publication: Results of the acceptability and feasibility study of the BPaL regimen (post)
TB Alliance and KNCV Tuberculosis Foundation published a study in BMC Public Health, focused on collecting stakeholder views (in Nigeria, Indonesia, and Kyrgyzstan) regarding the acceptability, feasibility, and likelihood of stakeholders implementing the BPaL regimen. BPal is a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.
Dashboard: Access to the BPaL regimen (post)
TB Alliance launched a webpage to provide information on national-level access to the BPaL regimen - a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.
Page 70 of 117 · Total posts: 0
←First 69 70 71 Last→